Spyre Presents Promising SPY001 IBD Data And Combination Therapy Results At DDW 2025
5/5 18:50
(RTTNews) - Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotech company focused on innovative antibody therapies for Inflammatory Bowel Disease or IBD and related immune disorders, Monday announced two poster presentations at Digestive Disease Week or DDW 2025, held from Ma...